Thomas L. Holland, MD, MSc-GH

Why ceftobiprole gains traction: infusion data and lab susceptibility reports help clinicians tackle stubborn Staph aureus bacteremia.

ERADICATE trial data show ceftobiprole is well-tolerated with mostly mild GI effects and no emerging resistance versus daptomycin.

FDA- and EMA-approved ceftobiprole matches daptomycin outcomes, offering a new beta-lactam option for MRSA bloodstream infections.

Inside the ERADICATE study: ceftobiprole matches daptomycin for complicated MRSA/MSSA bloodstream infections, expanding treatment options.

Staph aureus bloodstream infections remain deadly worldwide; vancomycin and daptomycin anchor MRSA bacteremia care, but dosing complexity, toxicity, and resistance persist.

Despite longstanding antibiotics like vancomycin and daptomycin, complicated Staphylococcus aureus infections—particularly MRSA—remain difficult to treat due to toxicity concerns, dosing complexity, and emerging resistance.

Despite modest progress, Staphylococcus aureus bloodstream infections—particularly those caused by MRSA—remain a major cause of morbidity and mortality, underscoring the urgent need for novel, broad-spectrum treatments such as ceftobiprole that can address both resistant and susceptible strains.